

Molecular Mechanisms of Myocardial Hypertrophy and Heart Failure

Experimental Studies on Cardiac G Protein-Coupled
Receptor Signaling with Emphasis on Endothelin-1

by

Thomas G. von Lueder

Institute for Surgical Research, Faculty Division Rikshospitalet

University of Oslo

Rikshospitalet University Hospital

Oslo, Norway

2008



© **Thomas G. von Lueder, 2009**

*Series of dissertations submitted to the
Faculty of Medicine, University of Oslo
No. 810*

ISBN 978-82-8072-799-2

All rights reserved. No part of this publication may be reproduced or transmitted, in any form or by any means, without permission.

Cover: Inger Sandved Anfinssen.
Printed in Norway: AiT e-dit AS, Oslo, 2009.

Produced in co-operation with Unipub AS.
The thesis is produced by Unipub AS merely in connection with the thesis defence. Kindly direct all inquiries regarding the thesis to the copyright holder or the unit which grants the doctorate.

*Unipub AS is owned by
The University Foundation for Student Life (SiO)*

Contents		page
1	Acknowledgements	3
2	List of papers	5
3	Abbreviations	6
4	Introduction	7
	Cardiac hypertrophy and remodeling in heart failure	9
	Endothelin system	10
	Inflammation in heart failure	15
	G protein-coupled receptor signaling and desensitization in heart failure	16
	G protein-coupled receptor kinases (GRKs)	18
5	Aims of the study	20
6	Summary of results	21
	Paper I	21
	Paper II	21
	Paper III	22
	Paper IV	22
7	Discussion	23
8	Conclusions	30
9	References	31

1. Acknowledgements

The present work has been carried out at the Institute for Surgical Research, Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, during the years 2001-2005, when I was a PhD student, and completed in 2008.

I am grateful to the Norwegian Council on Cardiovascular Diseases for granting me a research fellowship. Important and continuing financial support was also received from the MSD Cardiovascular Research Center, the Norwegian Society of Cardiology, the West-Norwegian Society of Cardiology, the Dr. Alexander Malthes Foundation, and the Alise Jelstrups Foundation.

I was fortunate to have highly merited cardiovascular scientist as my supervisors.

First, I am greatly indebted to my supervisor, professor dr. med. Håvard Attramadal, who introduced me to cardiovascular science and to the fascinating world which molecular biology is. His skilful guidance, critical advice in each and any step of this project, enthusiasm, encouragement, and friendship are most appreciated. Importantly, disregarding easy and fast tracks on the sometimes lengthy and painful journey before eventually submitting a paper, Håvard would always encourage us group members to meet his high standards. Prof. dr. med. Otto A. Smiseth has been my co-mentor and supervised in particular the physiology part of this work. His extraordinarily profound understanding of cardiac function, his critical revisions of drafts, and his brilliant ideas and insights have been essential for this work.

Professor dr. med. Ansgar O. Aasen and his staff at the Institute for Surgical Research are acknowledged for providing excellent working facilities, friendly atmosphere and support.

Chief veterinarian dr. med. Dag Sørensen with his staff is acknowledged for making available facilities at the Department of Comparative Medicine where most of the *in vivo* experimental work was carried out. The Center for Heart Failure Research, University of Oslo, and its

director prof. Geir Christensen are acknowledged for providing a broad and inspiring platform for presentation and discussion of our data.

This work includes studies of experimental models in swine, rats and mice, applying a wide range of methodology. Current state-of-the art integrative physiology and comprehensive molecular technology enabled us to explore answers to specific hypotheses. In this respect, a warm and special thanks goes to my colleagues and friends in the laboratory. All of them have made enormous contributions within their specific areas of expertise, and none of this work would have been possible without them: Leif Erik Vinge, Erik Øie, Harald Kjekshus, M. Shakil Ahmed, Thor Edvardsen, Stig Urheim, Birthe Mikkelsen, Joachim D. Paasche, Jørgen Graving; furthermore Ole-Jacob How, Ellen Aasum and Terje Larsen at the Dept. of Medical Physiology in Tromsø, and everybody I fail to mention here.

Experimental research demands commitment. The great days in the lab and the opportunities I was given to present our work at congresses abroad and in Norway made every effort worth it. Also, as mentioned before, my supervisors and colleagues made it easy to keep my personal flame of enthusiasm burning. I am glad to have had the opportunity to participate in several ongoing projects. Being a full time clinician for the last couple of years, the chance to study hemodynamics in men and mice has offered a great opportunity to learn more about cardiac function.

I am greatly indebted to my parents back in Regensburg, Germany to whom I dedicate this work, and to my brothers Michael, Arndt and Leif.

Most of all, I am deeply indebted to my wife Sylvie for all her support, encouragement, patience and love; and our beloved children Léo and Carla for their joy and inspiration, and for a daily reminder of what truly matters in life.

Oslo, December 2008

Thomas G. von Lueder

2. List of Papers

Paper I:

von Lueder TG, Kjekshus H, Edvardsen T, Øie E, Urheim S, Vinge LE, Ahmed MS, Smiseth OA, Attramadal H. Mechanisms of elevated plasma endothelin-1 in CHF: congestion increases pulmonary synthesis and secretion of endothelin-1. *Cardiovasc Res.* 2004; 63: 41-50

Paper II:

von Lueder TG, Øie E, Ahmed MS, Edvardsen T, Smiseth OA, Attramadal H. Macrophage depletion in heart failure attenuates cardiac remodeling by mechanism involving reduced secretion of endothelin-1 and pro-inflammatory mediators. *Submitted.*

Paper III:

Vinge LE, von Lueder TG, Aasum E, Qvigstad E, Gravning J, How OJ, Bjørnerheim R, Ahmed MS, Mikkelsen B, Øie E, Attramadal T, Skomedal T, Smiseth OA, Koch WJ, Larsen T, Attramadal H. Cardiac-restricted expression of the carboxyl-terminal fragment of GRK3 uncovers distinct functions of GRK3 in regulation of cardiac contractility and growth – GRK3 controls cardiac α 1-adrenergic receptor responsiveness. *J Biol Chem.* 2008;18;283(16):601-610.

Paper IV:

von Lueder TG, Gravning J, How OJ, Vinge LE, Ahmed MS, Larsen T, Smiseth OA, Aasum E, Attramadal H. Cardiomyocyte-restricted inhibition of GRK3 rescues cardiac dysfunction after chronic pressure overload. *Submitted.*

3. Abbreviations

β 1-AR	β 1-adrenergic receptors
AB	aortic banding
ACE	angiotensin-converting enzyme
Ang II	angiotensin II
EC	endothelial cells
ECE	endothelin-converting enzyme
ET	endothelin
GdCl ₃	gadolinium chloride
GPCR	G protein-coupled receptors
GRK	G protein-coupled receptor kinase
HF	heart failure
IL-12	interleukin-12
LV	left ventricle
LVEDP	left ventricular end-diastolic pressure
LVH	left ventricular hypertrophy
MCP-1	monocyte chemoattractant peptide-1
MI	myocardial infarction
NEP	neutral endopeptidase
PAH	pulmonary arterial hypertension
PCWP	pulmonary capillary wedge pressure
PVAN	pressure-volume analysis
RAAS	renin-angiotensin-aldosterone system
RCT	randomised controlled trial
RV	right ventricle
TNF- α	tumor necrosis factor- α
VSMC	vascular smooth muscle cells

4. Introduction

Heart failure (HF) is the common endpoint of heart disease of various etiologies, and is a major cause of hospitalizations and death worldwide(1-3). Essentially, HF represents a pathophysiologic state of impaired cardiac function in which the heart is unable to maintain cardiac output sufficient for adequate perfusion of organs and tissues (4; 5). Coronary artery disease, hypertension, cardiomyopathies and valvular disease represent major causes of HF. Projections are that the prevalence likely will increase as a consequence of increasing mean age of the population (6; 7). Furthermore, increased survival from myocardial infarction (MI) will leave more patients living with HF(8). Even with the best treatment currently available, the overall 5-years mortality of HF is still over 50% and thus, hardly better than that of many types of cancer, reflecting the fact that the pathogenetic mechanisms underlying HF are still incompletely understood. In addition to reduced capacity of the heart to pump blood, HF is associated with activation of pro-inflammatory responses and mediators which itself can lead to progressive deterioration of cardiac function(9-11). More detailed knowledge of molecular mechanisms of HF has become a subject of intensive research. Chronic alterations in structure and geometry of the cardiac muscle, so-called remodeling, are widely found in heart failure patients(12; 13). Left ventricular (LV) remodeling itself is a progressive process which often is initiated by stress events or biomechanical loading such as myocardial infarction and poorly controlled hypertension(12; 13). As a paradigm, remodeling can either be predominantly eccentric (i.e. the heart is dilating), concentric (muscle mass is increasing) or a combination of both(13; 14). Basic research and translation of its results into clinical trials has seen major recent advances and led to the establishment of new treatment modalities targeting β -adrenergic signaling, Ang II and aldosterone activation(15-18).

Cardiac function is controlled by the autonomic nervous system, hormones, and diverse autocrine, endocrine or paracrine factors. G protein-coupled receptors (GPCR) comprise a

major class of receptors, and are in fact one of the largest known protein families(19). GPCRs are involved in most fundamental biological signaling processes, and in essence in most of mammalian tissues(20; 21). The vital importance of GPCR signaling in cardiac disease is illustrated by the fact that the vast majority of current cardiovascular drugs target specific GPCRs, such as β 1-AR, angiotensin type-II receptors, aldosterone or endothelin (ET) receptors(17; 18; 22; 23).

Increasing knowledge of signaling mechanisms in cardiac physiological and pathological states will be crucial for improving treatment of the HF and its precursing disease entities. Furthermore, targeted interaction with key pathophysiological signaling mechanisms holds the potential of preventing evolution to cardiac hypertrophy and HF upon given stress signals, as has been shown in numerous experimental studies. The present work aims to explore novel molecular mechanisms in hypertrophy and HF, as well as to investigate potential therapeutic principles.




Fig. 1 Adaptive and maladaptive cardiac hypertrophy (modified from Frey et. al. (24))

Cardiac hypertrophy and remodeling in heart failure

Cardiac hypertrophy, i.e. excessive growth of the heart, can initially occur by cardiomyocyte hyperplasia, but primarily by increase of cell mass. Postnatal cardiac growth is a normal physiological phenomenon aiming at increasing heart size, i.e. to maintain cardiac output in the growing organism or to meet increased bodily demands during exercise training. Pathological stimuli such as catecholamine excess or increased afterload can lead to maladaptive cardiac hypertrophy, as seen in hypertension or aortic stenosis. Multiple signaling and transcription pathways are involved in this process, leading to hypertrophic remodeling of the LV (fig. 1)(24; 25). This type of LV hypertrophy (LVH) is an independent risk factor for cardiac morbidity and mortality(26). In HF patients, elevated levels of catecholamines are frequently seen(27; 28). Sustained adverse stimulation will increase

cardiomyocytes and thus, cardiac mass, both through increased afterload or direct cardiac effects. Among the adrenergic receptors, α_1 -AR couple to the heterotrimeric G-protein G_{α_q} . Upon agonist activation, the G_{α_q} unit activates phospholipase C, which increases inositol-1,4,5-triphosphate and diacylglycerol. The former increases intracellular calcium, while the latter leads to further activation of PKC isozymes(29). The G_{α_q} pathway has been extensively studied for its importance in cardiac hypertrophy and HF(30). Based on a body of largely experimental evidence; one may suggest that factors leading to hyperactive G_{α_q} signaling predispose to cardiac hypertrophy, and potentially, transition to decompensated HF(31-35). Neuroendocrine factors and cytokines such as ET-1 and AT-II promote activation of important downstream signaling cascades including MAPK, calcineurin, NFAT/GATA4, PKC, CaMK, and IGF-1 pathway constituents(36; 37). One important issue relating to GPCR-mediated hypertrophy and HF is to delineate specific signaling complexes in order to ascertain critical intracellular events regulating the hypertrophic response and transition to HF(38).

Endothelin system

Endothelin (ET) is a 21-amino acid peptide first isolated from porcine endothelial cells.(39) Three isoforms encoded by separate genes exist; ET-1, ET-2 and ET-3(39; 40). ET-1, the major isoform of the endothelin peptide family in the cardiovascular system, is among the most potent vasoconstrictors (~100 x norepinephrine) known to date, and possesses as positive inotropic and chronotropic effects (41-44), mitogenic effects on smooth muscle cells (45), influence on salt and water homeostasis, and stimulation of the renin-angiotensin-aldosterone (RAAS) and sympathetic nervous systems (for reviews, see (46; 47) (fig. 2).




Fig. 2 The vascular endothelin (ET) system (modified from Kirkby et al (48))

ET-1 is essential for normal embryonic development (49; 50). The biosynthesis of ET-1 occurs through several proteolytic steps to form the prohormone prepro-ET, the inactive intermediate big ET-1, which is subsequently processed by endothelin-converting enzyme (ECE) into biologically active ET-1 (Fig. 2)(51). Two isoforms of ECE with distinct pH-optima, ECE-1 and ECE-2, with 4 and 2 subtypes, respectively, have been characterized(51-55). In vivo, the activity of ECE-1 appears to be the rate-limiting step in ET-1 biosynthesis(56; 57).

Table 1. Function of ET receptors in the cardiovascular system.

Cell type	ET_A receptors	ET_B receptors
Cardiomyocytes	Hypertrophy(58) Positive inotropy(41) Protection from apoptosis(59)	Positive chronotropy(42) Hypertrophy?
Cardiac fibroblasts	Growth, fibrosis(60-62)	Growth, fibrosis(63; 63; 64)
Endothelial cells		Vasodilation through the release of NO and prostacyclin(65) and adrenomedullin(66) ET-1 clearance/reuptake(67) Increased ET-1 gene expression(68)
Vascular smooth muscle cells	Vasoconstriction, growth (45; 69)	Vasoconstriction(70)

ET-1 is mainly produced by endothelial, vascular smooth muscle cells, and macrophages and acts through binding to Gq-protein-coupled ET_A and ET_B receptors(71). In the cardiovascular system, ET_AR and ET_B R signaling produces distinct effects (table 1). Within the vasculature, ET-1 is secreted predominantly abluminally, i.e. on the basal side of endothelial cells to act on vascular smooth muscle cells (VSMC)(72), resulting in substantially higher concentrations within the vascular wall compared to plasma levels. Under normal physiological conditions, ET-1 plasma levels are low, with ET-1 acting rather as a paracrine factor(73). In cardiac disease such as HF, ET-1 levels are elevated and thought to derive primarily from spillover in the vasculature(74-79). Several reports have shown that the pulmonary circulation contributes to circulating plasma ET-1 levels in HF(80; 81). The synthesis and secretion of ET-1 by endothelial cells is increased by various growth factors, cytokines and vasoactive factors, such as Ang II, vasopressin, bradykinin, norepinephrine and ET-1 itself (82). Low shear stress increases ET-1 mRNA, while high shear stress decreases it (83; 84). The clearance of ETs from plasma may occur through cleavage by neutral endopeptidase EC3.4.24.11 (85), and through binding to ET_BR, which especially in the lung acts as a clearance receptor (86; 87). Due to effective clearance, the plasma half life of infused ET-1 is only one minute (47).

Importantly, ET-1 contributes in the pathogenesis of post-MI remodeling and HF, and plasma levels strongly predict mortality and morbidity(75; 76; 88-90). In this condition, ET-1 increases afterload by peripheral ET_AR mediated vasoconstriction(91-93). Moreover, ET-1 levels are increased in relation with the severity of pulmonary arterial hypertension (PAH) in HF; likewise, ETR inhibition ameliorate the degree of PAH in animals and patients with HF.(94-98). On the contrary, short-term therapy aimed at lowering afterload and elevated filling pressures in HF patients rapidly reduced ET-1 and neurohormonal activation (99). Based on encouraging experimental data (100) and human hemodynamic studies, several randomised controlled trials (RCT) have explored the putative benefit of ETR blockade in HF patients (table 2). Both dual or non-selective receptor blockers (targeting ET_AR and ET_BR) and selective ET_AR blockers have been employed. To date, the vast majority of these trials have failed to show improved outcome. However, in patients with isolated PAH, an infrequent yet rapid progressive and incurable cardiovascular disease leading to right-sided HF, non-selective ET receptor blockade has consistently demonstrated favourable outcomes(101). For this type of patients, ET-1 receptor blockers Bosentan, and more recently, Sixtasentan and Ambrisentan, have been added to the list of efficient pharmacotherapy(102). Despite recent major advances in ET research, many aspects of ET biology and in particular, origin, role and fate of elevated plasma ET-1 in HF are still poorly understood.

Table 2. Randomized controlled trials of ET antagonism in human HF.

Acute HF	Intervention	N pat.	Outcome	Comment	Reference
Pilot study	Tezosentan 20 or 50 mg/h IV for 24 h	14	Improved systemic and pulmonary hemodynamics	Safety-trial. Control group received dobutamine.	(103)
Pilot study	Tezosentan 5-100 mg/h IV for 6 h	61	Improved systemic and pulmonary hemodynamics	Hemodynamics and safety-trial. No serious adverse events	(104)
RITZ-1	Tezosentan 25 mg/h IV for 1 h, then 50 mg/h for 24-72 h	669	No differences in end points	More renal failure and hypotension in Tezosentan group	(105)
RITZ-2	Tezosentan 50 or 100 mg/h IV	240	Improved systemic and pulmonary hemodynamics at 6 h	No serious adverse events	(106; 107)
RITZ-4	Tezosentan 25 mg/h IV for 1h, then 50 mg/h for 24-48 h	193	No differences in end points	HF patients with ACS. More symptomatic hypotension in Tezosentan group.	(108; 108)
RITZ-5	Tezosentan 50-100 mg/h IV for 24 h	84	No differences in end points	Pat with fulminant PE. Better outcome with 50 mg dose. More side effects with higher doses	(109)
VERITAS-1 and 2	Tezosentan 5 mg/h for 30 min, so 1mg/h for 24-72 h	730	Non-significant benefit	More hypotension in Tezosentan group. Discontinued early for presumed lack of benefit.	(110; 111)
Chronic HF	Intervention	N pat.	Outcome	Comment	Reference
Pilot study	Bosentan 1000 mg PO BID for 2 weeks	36	Improved systemic and pulmonary hemodynamics	N=24 Bosentan vs N=12 placebo	(112)
REACH-1	Bosentan 250 mg PO BID	370	No differences in end points; trend to lower mortality	Trial stopped early. Toxic effects. Unpublished.	(113)
ENABLE-1 and 2	Bosentan 125 mg PO BID for 9 months	1613	No differences in end points	9 months follow-up. Early worsening of HF in Bosentan group. Unpublished.	(114; 115)
HEAT	Darusentan 3 different doses PO	157	Improvements in CI by Darusentan	More side effects at higher doses	(116)
ENCOR	Enrasentan (unpublished)	419	No differences in end points	Trend for increased rate of hospitalization. Unpublished.	(117)
EARTH	Darusentan 10-300 mg PO for 24 weeks	642	No differences in end points (LV volumes by MRI)	Increased adverse effects	(118)

ACS, acute coronary syndromes; CI, cardiac index; PCWP, pulmonary capillary wedge pressure; BID, twice daily; PE, pulmonary edema;

Inflammation in heart failure

Among multiple compensatory processes being activated as beforementioned, chronic HF is characterized by inflammatory responses and activation of the innate immunity. Recently it has been shown that patients with HF have increased plasma and myocardial levels of inflammatory cytokines(9; 10; 119-123). Among proposed mechanisms for this immune activation, which are not mutually exclusive, are neurohormonal activation, hemodynamic overload, and activation of the innate immune system secondary to cardiac stress events, i.e. myocardial infarction. Experimental data have demonstrated a role for inflammatory and vasoactive cytokines such as tumor necrosis factor- α (TNF- α), interleukin-1 (IL-1), ET-1, and monocyte chemoattractant peptide-1 (MCP-1), all of which may contribute to the development and progression of HF by promoting myocardial hypertrophy or dysfunction, extracellular matrix remodeling, inducing apoptosis(9; 10; 119-124). Uncertainties exist as to the organ and cellular source of many of these cytokines, but the clinical significance is illustrated by a consistent and significant correlation of plasma levels and clinical outcomes(122; 125-128). Both TNF- α and ET-1 are such proinflammatory cytokines which can be produced by macrophages. Importantly, cardiac overexpression of TNF- α (129) or ET-1 (130) in mice leads to similar phenotype of inflammatory cardiomyopathy. Currently, only few experimental and human studies have addressed the question whether targeting of an overactivated immunity in HF may carry benefit. “Single target” approaches such as blockade of TNF- α receptor in patients with HF have not demonstrated outcomes superior to conventional treatment, while more broad-based anti-inflammatory strategies demonstrated clinical improvements (131-135). More research in this area is needed to precisely identify important mechanisms in the immunopathogenesis of chronic HF which then could be counteracted pharmacologically.

G protein-coupled receptor signaling and desensitization in HF

Cardiac output is normally regulated by the autonomic nervous system and can be increased through release of stress hormones such as catecholamines. Catecholamines such as norepinephrine transmit their “message” through G protein-coupled receptors (GPCR), whose common feature is a seven-transmembrane span and their ability to activate heterotrimeric G-proteins. Activation of G-proteins initiates transduction of the extracellular signal to intracellular effector molecules(136). In the heart, GPCRs signaling may regulate function by modulating heart rate and contractility, or structure by inducing events such as cell growth or death (apoptosis). As a typical example for the GPCR-related signaling cascades, agonist binding to β 1-adrenergic receptors (β 1-AR) in the heart will activate the G protein G_{α_s} (s, stimulatory). Activated G_{α_s} will then activate adenylyate cyclase (AC), leading to AC-catalyzed synthesis of cAMP. Functioning as a second messenger, cAMP then activates protein kinase A (PKA), leading to positive chronotropy (increased heart rate), inotropy (increased contractile force) and lusitropy (quicker relaxation)(137-140). β 1-adrenergic receptors (β 1-AR) are the predominant cardiac GPCRs activated by endogenous norepinephrine and epinephrine, with minor contributions by β 2-AR and, at least in some mammalian species, α 1-AR(141; 142). In HF irrespective of the initiating event, compensatory mechanisms such as augmentation of β 1-AR signaling are rapidly activated, in order to maintain sufficient cardiac output. This is afforded at the cost of increased heart rate and myocardial oxygen consumption. Prolonged activation of β 1-AR, moreover, can induce programmed cell death of heart muscle cells (cardiomyocyte apoptosis), reduced number as well as reduced response of receptors, and ultimately worsening of cardiac function(142; 143). The deleterious consequences of chronic neurohormonal overactivation suggest an important protective role for mechanisms which desensitize neurohormone-mediated GPCR responses in HF. Based on these fundamental molecular events, β 1-AR blockade has

emerged as a major therapeutic principle in heart failure during the last decade. Activation of the renin-angiotensin-aldosterone system (RAAS) is another important mechanism activated in HF, leading to increased circulating and myocardial levels of the vasoconstrictor peptides renin and angiotensin II as well as the mineralocorticoid hormone aldosterone. All of these three components of the RAAS are established or emerging drug targets in heart failure(15-18). In HF, loss of response due to prolonged or augmented activation of GPCRs such as the β -AR has been identified, a phenomenon termed receptor desensitization (138; 144-146). Receptor desensitization can occur quickly, experimentally even after a few seconds or minutes. Also, desensitization can either be limited to agonists acting at a particular GPCR subtype, referred to as homologous desensitization, or represent a more general loss of agonist responsiveness involving several GPCR even in the absence of agonist occupation of these receptors. The former usually involves changes at the level of the GPCR itself, while the latter may involve adaptive changes in downstream signaling components. Importantly, desensitization is a process distinct from GPCR downregulation, which involves lysosomal degradation of GPCRs. Even excessive GPCR desensitization does not necessarily lead to downregulation, but both can occur simultaneously, adding to loss of functional response upon agonist stimulation. An important mechanism in the 'classical' model of agonist-induced desensitization is phosphorylation of the GPCR(147). Phosphorylation is catalyzed by a family of kinases termed G protein coupled receptor kinases (GRK). GRK have been demonstrated to play a key role in agonist-induced phosphorylation and desensitization of numerous GPCR mediated responses. The classical model for agonist-occupied desensitization of GPCR involves phosphorylation of serine or threonine residues on the 3rd intracellular loop or COOH- terminus of the GPCR(148). Arrestins, members of another family of regulatory proteins, then bind to the GRK-phosphorylated GPCR with high affinity,

uncoupling it from further G-protein activation, thus inducing desensitization of the GPCR.




Fig. 3 The G protein-coupled receptor kinase (GRK) family

G protein-coupled receptor kinases (GRKs)

GRKs constitute a family of seven serine/threonine protein kinases which are further subdivided into three main subgroups, i.e. visual GRKs or the rhodopsin kinase subfamily (GRK1 and GRK7), the βARK kinase subfamily including GRK2 (βARK1) and GRK3 (βARK2), and the GRK4 family (GRK4, GRK5, and GRK6) (fig. 3)(149).

In myocardial tissue, 4 different GRKs have been found, GRK2, 3, 5 and 6. Of these, GRK2 and GRK3 share important structural similarities. In contrast to the other GRKs, GRK2 and GRK3 possess a carboxy-terminal (CT) pleckstrin-homology (PH) domain important for membrane targeting and binding to G-protein subunits(149). GRK2, initially termed βARK1,

has been shown to mediate desensitization of myocardial β -AR(150; 151). In experimental and human HF upregulation of myocardial GRK2 is found(152; 153). Inhibition of GRK2 in genetically engineered mouse models of heart failure, such as the muscle *lim* protein–knockout model and cardiac-specific overexpression of calsequestrin, and in a number of experimental settings has provided robust evidence of improving cardiac function and survival(150; 154-159). Although similar overall structure, GRK3 has distinct substrate specificities determined by the CT domain. While GRK2 regulates cardiac β -AR and Ang II-R, α 1-ARs are not touched by it(150; 160; 161). Vice versa, GRK3 strongly modulates cardiac α 1-AR, ET-R and thrombin receptor mediated responses without altering β 1-AR mediated responses or receptor internalization(160-162). Accordingly, GRK2 and GRK3 seem to have distinct substrate specificities at least within the cardiovascular system (table 3). The role of myocardial GRK3 is little studied, as is its potential involvement in cardiac disease states, and the role of GRK5 and GRK6 are almost unknown. Several powerful molecular strategies have emerged during the last decade and proven valuable tools to study GRK isozyme function in vitro and in vivo.

Table 3. Substrate preferences of GRK2 and GRK3 in cardiovascular tissues.

Receptor	GRK2	GRK3	References
β 1	+	-	(150; 160; 162)
β 2	+	-	(163)
α 1	-	+	(160-162)
ET	-	+	(162)
Angiotensin II	+	-	(160; 164)
Thrombin	-	+	(160; 165; 166)
Muscarinic	?	+(?)	(167)

5. Aims of the Study

This work aimed to elucidate molecular mechanisms involved in the pathophysiology of cardiac hypertrophy and heart failure.

The specific aims of the study were:

- 1) to identify the origins of increased plasma ET-1 levels in HF
- 2) to elucidate the mechanism of increased pulmonary secretion of ET-1 in experimental HF
- 3) to investigate whether depletion of macrophages reduces pulmonary ET-1 secretion and progressive cardiac remodeling in HF
- 4) to elucidate the role of GRK3 in regulation of myocardial function *in vivo*
- 5) to investigate to what extent inhibition of GRK3 *in vivo* alters development of pathological cardiac hypertrophy and HF after pressure-overload

6. Summary of Results

Paper I

Juvenile pigs subjected to three weeks of rapid cardiac pacing exhibited significant left ventricular dilatation and dysfunction, increased cardiac filling pressures, and over 4-fold increase of arterial plasma ET-1 levels, consistent with induction of severe HF. Repeated investigations showed an increasing trans-pulmonary gradient of plasma ET-1 during evolving HF. Single-bolus multiple indicator-dilution experiments revealed increased pulmonary synthesis and release of ET-1 in HF, with pulmonary clearance of ET-1 remained unaltered. ECE-1 isozyme activity was selectively increased in congested pulmonary tissue of HF pigs, and correlated significantly with the wet/dry weight ratios of the samples, i.e. a marker of pulmonary congestion. Furthermore, pulmonary macrophages (PM) in congested lobe segments were identified as likely sites of increased synthesis and release of ET-1.

Paper II

Two weeks (baseline) after induction of myocardial infarction by coronary ligation, rats in severe HF were randomized to treatment with the macrophage toxicant gadolinium chloride $GdCl_3$ (HF-Gad) or vehicle (HF-V) for 21 days (end-point). In HF-Gad compared to HF-V rats, massive apoptosis of PM and lower pulmonary tissue levels of the macrophage-derived cytokines IL-12A and IL-12B and ET-1 were found. Arterial plasma ET-1 levels were increased 6-fold in HF-V rats vs. sham-operated rats. Depletion of PM led to reduced arterial plasma ET-1 levels and eliminated the trans-pulmonary gradient of ET-1. Moreover, HF-Gad rats exhibited halted progression of cardiac dilatation and dysfunction and significantly reduced filling pressures.

Paper III

Cardiac function of GRK3 was investigated in transgenic mice (Tg-GRK3ct) with cardiac-specific expression of the carboxyl-terminal portion of GRK3 (GRK3ct) to inhibit its

activation through $G_{\beta\gamma}$ -directed membrane translocation. Tail-cuff plethysmography of 3-9 months old Tg-GRK3ct mice revealed modest hypertension compared to non-transgenic littermate control (NLC) mice, an observation confirmed by blood pressure radiotelemetry of conscious, unrestrained mice. Heart rate, however, was similar between Tg-GRK3ct and NLC mice. Young Tg-GRK3ct mice (3 months) had normal cardiac dimensions but enhanced contractility. Moreover, Tg-GRK3ct mice displayed supersensitivity to α_1 -adrenergic receptor stimulation, while response to chronic β_1 -adrenergic receptor stimulation was unaltered. Pressure-volume relationships obtained in electrically paced *ex vivo*-perfused working hearts confirmed hypercontractile myocardium with elevated dP/dt_{max} , LV developed pressure, cardiac output, and stroke work in Tg-GRK3ct mice at physiological filling pressures.

Paper IV

Here we sought to elucidate the putative role of myocardial GRK3 in the development of pathological cardiac hypertrophy and HF. Tg-GRK3ct and NLC mice were subjected to chronic pressure-overload by suprarenal abdominal aortic banding (AB). Six weeks after AB, pressure-volume analysis of *ex vivo* perfused working hearts revealed substantial systolic and diastolic cardiac dysfunction in NLC mice, while cardiac function was entirely preserved in banded Tg-GRK3ct mice. Cardiac and LV mass was significantly enhanced in banded compared to their respective sham groups confirming LVH, but without significant differences between banded Tg-GRK3ct and NLC mice. At 12 weeks after AB, NLC mice displayed increased LV filling pressures, reduced cardiac output and augmented myocardial mRNA levels of BNP consistent with HF, all of which were prevented in banded Tg-GRK3ct mice.

7. Discussion

This thesis sheds light on novel molecular mechanisms involved in the pathogenesis of myocardial hypertrophy, LV remodeling, and HF. Comprehensive integrative physiology and molecular techniques were applied in a range of ischemic and non-ischemic HF models in pigs, rats and mice, to elucidate important components of GPCR signaling.

Origin and mechanisms of elevated ET-1 levels in HF

In a large animal model of tachycardia-induced HF, we studied the tissue-specific and cellular origin of increased plasma ET-1 levels. In HF, ET-1 may act in an endocrine fashion, and several reports have indicated the lungs to play a contributing role to increased plasma levels, but the relative importance of the pulmonary compared to other vascular beds had not been established(80; 81). We here not only demonstrate the pulmonary circulation to be the most important source of elevated plasma ET-1, but also show that the trans-pulmonary gradient of ET-1 increased with progression of HF. The lungs efficiently remove ET-1 from the circulation via binding to its presumed clearance receptor ET_BR(86; 87; 168). Other investigators have previously found reduced pulmonary density of ET_BR and reduced fractional extraction of ET-1 in HF models, indicating failure of the lungs to remove ET-1 in HF(80; 169). The relative contributions of altered clearance or production of ET-1 to raise plasma ET-1 levels in HF remained yet to be investigated(87; 168; 170). We found the pulmonary fractional extraction of plasma ET-1 to be about halved in HF pigs. However, fractional ET-1 extraction does not take into consideration the circulating plasma volume per time unit (cardiac output). Clearance of ET-1, i.e. the absolute amounts of ET-1 being removed from the circulation per minute, was not altered, contrasting with previous reports(80). However, that study was performed in rats with HF post-MI, and with ET-1 clearance determined in lungs *ex vivo*. Another important finding of the present study was that

pulmonary synthesis of ET-1 was enhanced and correlated significantly with markers of LV filling pressures (LVEDP and PCWP). Augmented ECE-1 activity in congested pulmonary tissue was identified as important molecular mechanism for increased pulmonary synthesis of ET-1 in HF. These novel findings clearly illustrate the relevance of pulmonary congestion and pulmonary endothelial dysfunction for ET-1 activation.

Caution has, however, to be exerted when extrapolating these data in order to reach a broader understanding of HF. The pacing overdrive model employed here induces homogenous eccentric LV remodeling, generating a stable, predictable and relatively homogenous experimental HF cohort, but cardiac ultrastructural changes may differ from those observed in HF post MI(171; 172). Yet, LV dilatation and dysfunction, peripheral vasoconstriction, and neurohormonal activation including that of the ET-1 system, share important similarities with human dilated HF(173-177).

Possible implications for future management of HF

ET-1 is a multifunctional peptide governing numerous and complex biological functions in the cardiovascular system. The data presented in this study underbuild the notion that ET-1 is an important player in the pathogenesis of HF. Targeting of GPCRs in HF is of proven benefit in the case of β 1-AR, but has not produced similar beneficial outcomes when targeting ETR. In the future, alternative approaches to counteract ET-1 mediated actions should be pursued, such as targeting biosynthesis at its molecular and cellular sources. ECE-1 inhibitors have been shown to produce similar acute vasodilator effects as ET_AR antagonists in HF patients already on ACE inhibitor treatment(91; 178). ECE-1 antagonists have been shown to normalize ET-1 levels; and several approaches targeting ECE-1 individually or as dual ECE-1/NEP inhibition or triple ECE-1/NEP/ACE inhibition have produced functional benefits in experimental and human HF(179-184). Besides ECE-1, also NEP and chymase may convert

bigET-1 to fully mature ET-1; thus, agents inhibiting multiple peptidases may be required. However, as both ECE-1, NEP and ACE also participate in the hydrolysis of bradykinin, putative adverse effects by accumulation of bradykinin need to be considered when triple inhibitors are employed(185; 186). Data from larger RCTs testing the concept of inhibiting ET-1 biosynthesis are lacking(48; 184).

Effects of macrophage depletion on ET-levels and LV remodeling in HF after MI

In the second paper, following up on findings in paper 1, we aimed to further explore the importance of specific components of the innate immunity, i.e. PM, for ET-1 synthesis and HF progression. Based on successful protocols of PM targeting in a model of PAH and right-sided HF, we administered GdCl₃ in the classical ischemic HF rat model, commencing two weeks after induction of a large MI with evidence of HF(187). Immunohistochemical and molecular analysis indicated successful PM depletion. The study provided first evidence that targeting PM significantly reduced systemic and pulmonary ET-1 levels as well as halted cardiac remodeling. There are several important considerations relating to the intervention as well as the assumed mode of action of GdCl₃. Neither GdCl₃ itself nor the chosen route of administration may provide entirely selective and specific targeting of PM. More likely, GdCl₃ may affect several types of actively phagocytosing cells in liver and lungs as well as other organs, i.e. liver, spleen and kidneys(188; 189). For instance, there is evidence that GdCl₃ interferes with hepatic Kupffer cell function, and reduces pro-inflammatory cytokines in sepsis or liver ischemia-reperfusion models(190-195). Moreover, even after first passage through the lungs, relevant amounts of GdCl₃ could have reached the myocardium to exert positive inotropic effects as demonstrated at least *in vitro* in a dilated cardiomyopathy HF model(196). Nevertheless, several lines of evidence support the effectiveness of the intervention: First, massive apoptosis of CD68-positive cells in lung tissue were found in

GdCl₃-treated HF rats. Next, cardiac tissues showed only few CD68 positive cells, little apoptosis, and no differences between HF groups (data not shown). Last, trans-pulmonary gradients of plasma ET-1 as well as pulmonary tissue ET-1 and IL-12A and IL-12B levels were substantially reduced by the intervention. However, due to the small animal size, it was not feasible to perform experiments deciphering the relative contribution of pulmonary clearance and synthesis of ET-1, as in paper 1.

The putative importance of PM in ET-1 biosynthesis and functional progression in HF needs to be corroborated in future studies. Both application of tissue- and cell-specific drugs and genetic targeting of PM or PM-related cytokines may be valuable and technically feasible strategies.

Inhibition of myocardial GRK3 *in vivo* enhances contractility and α 1-AR signaling

Specific aspects of GPCR signaling, i.e. the role of myocardial GRK3 in regulation of cardiac function *in vivo*, were addressed in papers III and IV. GRK2 (formerly β ARK-1), the isozyme of GRK3 has been shown to be regulated in experimental and human HF, and inhibition of GRK2 provided rescue of cardiac function in several HF models(150; 152; 153; 155-159). GRK3, previously thought to be subservient to its isozyme GRK2, is increasingly appreciated as a novel important regulatory kinase. Unlike GRK2, GRK3 does not seem to be regulated in cardiac tissue in HF(197). However, its selective expression in cardiomyocytes may imply an important functional role(197). Previous studies, performed in transgenic mice with cardiac-restricted overexpression of GRK3, revealed specificity of GRK3 to desensitize α 1_B-AR and thrombin receptor, while β 1-AR and Ang II signaling were not altered(160; 161). To date, studies of cardiac-specific targeting of GRK3 *in vivo* are lacking. A recent report from our laboratory provided *in vitro* evidence of striking differences in receptor specificities of GRK2 and GRK3 in adult rat cardiomyocytes(162). It could be clearly shown that GRK3, but not

GRK2, regulated α 1-AR and ET-R, while GRK2 or its peptide inhibitor reduced and enhanced β 1-AR signaling, respectively. To study these findings *in vivo*, we generated transgenic mice expressing a peptide inhibitor of GRK3 (GRK3ct) in the myocardium, which exhibit phenotype with enhanced cardiac function and elevated blood pressure. Evidence of subtle LV diastolic dysfunction was found in the GRK3ct mice although the relevance of these *ex vivo* findings at very high filling pressures is uncertain. By *ex vivo* and *in vivo* experiments, GRK3 was identified to modulate α 1-AR and ET-R, but not β 1-AR. The dominant α 1-AR subtypes in mice appear to be α 1_A-AR and α 1_B-AR. While cardiac-restricted overexpression of the α 1_A-AR in transgenic mice increased contractility in the absence of hypertrophy, overexpression of the α 1_B-AR induced early diastolic dysfunction and progression towards overt dilated HF later on (198-200). We did not succeed in identifying which α 1-AR subtype was modulated most by GRK3ct expression, but the phenotypic findings point to predominant augmentation of α 1_A-AR signaling.

Several aspects of the study, in particular relating to the transgenic model need to be discussed as important limitations. Cardiac myocyte-restricted expression of an inhibitory peptide, i.e. GRK3ct; may not only inhibit GRK3; an argument already raised in the case of GRK2ct. Apart from GRK3, other PH domain-containing proteins might be inhibited.

GRK3ct may in fact inhibit GRK2, and although data obtained in rat cardiomyocytes *ex vivo* demonstrated selectivity of GRK3ct peptides for GRK3, we cannot exclude such effects to occur in mice *in vivo* (162). However, the lack of enhanced β 1-AR signaling in the present study argues against relevant inhibition of GRK2. Moreover, even though not observed in our experiments, downstream regulation by sequestration of G β γ could have occurred, leading to altered G β γ -mediated signaling. However, the distinct specificities of GRK3ct compared to GRK2ct at the functionally most important cardiac GPCR and the similar specificities of the corresponding kinases GRK3 and 2 argue against sequestration of G β γ (162).

To substantiate the findings presented here, alternative routes of manipulating GRK3-mediated signaling should be pursued. For instance, targeted deletion of cardiac GRK3 (i.e. cardiac specific knock-out of GRK3, GRK3-KO) could be performed. Previously, enhanced chronotropic component of the baroreceptor reflex has been described in a general GRK3-KO model(167). However, blood pressure was not determined in that paper, making judgments on possibly altered β 1-AR mediated enhancement of heart rate after nitroprusside administration difficult. Also, the lack of cardiac-selectivity in that genetic model obscures interpretation, and to date no further studies have been conducted attempting to clarify these findings. To gain more knowledge on putative dose-response effects of GRK3 manipulation on distinct GPCR signaling, supplemental functional studies in transgenic mice with different cardiac expression levels of GRK3 or an inhibitor would be needed.

GRK3 inhibition rescues pressure-overload induced cardiac dysfunction

In paper four, we extended our study on the regulatory role of GRK3 on cardiac function into a pathophysiological setting. In a pressure-overload model, inhibition of GRK3 prevented development of HF, and preserved cardiac function, while induction of pathological LVH itself was not altered. To exclude peripheral circulatory effects, comprehensive analysis of LV pressure-volume relations both *in vivo* and *ex vivo* were performed. An interesting observation is the lack of GRK3ct to augment increases of cardiac mass after pressure-overload, compared to our findings after chronic α 1-AR stimulation. This behaviour resembles indeed that of GRK2ct in comparable settings(201; 202). One readily available explanation might be a concomitant GRK3ct-mediated enhancement of pro-hypertrophic pathways such as via α 1_B-AR, being counteracted by beneficial α 1_A-AR-mediated enhancement of cardiac function in resisting high afterload, resulting in a neutral net effect on cardiac mass. In addition, pressure-overload induced hypertrophy also occurs through activation of neurohormones such as Ang

II and ET-1; mediators which did not evoke enhanced ERK1/2 activation in cardiomyocytes of GRK3ct mice compared NLC mice (fig. 6, paper 3). Phosducin, a G $\beta\gamma$ -binding protein that does not resensitize β -ARs, enhances contractility of failing cardiomyocytes in a similar fashion as GRK2ct(203), and in the absence of increased β -AR-stimulated cAMP formation. Conceptually, the effects of GRK2ct could at least partially be due to inhibition of G $\beta\gamma$ rather than β -AR resensitization. In view of the current findings that GRK3ct mediates similar cardioprotection as GRK3ct, at least some of the beneficial effects could involve signal transduction via common downstream pathways, including G $\beta\gamma$ -mediated effects. Recent data showed G $\beta\gamma$ -dependent phosphoinositide 3-kinase (PI3K) activation in afterload-induced cardiac hypertrophy(204). The same group also demonstrated PI3K to form a cytosolic complex with GRK2, leading to GRK2-mediated translocation of PI3K to the membrane with subsequent attenuation of β -AR sequestration (205). These data were supported by evidence for preserved β -AR function and restored cardiac function through inhibition of receptor-localized PI3K in several HF models (206; 207).

In order to decisively establish a protective role for GRK3 inhibition in HF, several strategies would be applicable. MI-induced HF or volume overload models would need to be applied in order to address the impact of particular stressor stimuli on GRK3 signaling. Ongoing projects are going to evaluate cardiac function in hybrids of GRK3ct mice or mice with cardiac-specific GRK3-KO cross-bred with genetic HF mice. Findings obtained in experimental models may eventually be tested by adequate pharmaceutical interventions, i.e. application of small-molecule approaches(208). If successful, this may provide the basis for testing GRK3 modulation in human HF.

8. Conclusions

1. In a large animal model, the lungs were identified as the most important contributors to elevated plasma ET-1 levels in severe HF. Pulmonary synthesis and release of ET-1 were increased, while pulmonary clearance of ET-1 remained unaltered. Increased ECE-1 isozyme activity in congested pulmonary tissue was identified as an important mechanism, with pulmonary macrophages (PM) appearing as novel cellular sites of increased synthesis of ET-1.
2. In post-MI HF in rats, treatment with the macrophage toxicant GdCl₃ for 21 days induced massive apoptosis of PM, lowered inflammatory cytokines and plasma levels of ET-1, and eliminated the trans-pulmonary gradient of ET-1. Importantly, macrophage depletion halted progressive cardiac dysfunction and HF after MI.
3. Cardiac-specific inhibition of GRK3 in transgenic mice induces modest cardiac hypercontractility and hypertension, with structurally normal hearts. GRK3 inhibition increased responsiveness to α_1 -AR stimulation, while response to β_1 -AR stimulation was unaltered.
4. Inhibition of GRK3 did not affect cardiac hypertrophy upon chronic pressure-overload. However, cardiac function was preserved in Tg-GRK3ct compared to NLC mice, indicating a protective role of GRK3 inhibition in this HF model.

9. References

1. **Ho KK, Anderson KM, Kannel WB, Grossman W and Levy D.** Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation* 88: 107-115, 1993.
2. **Dargie HJ and McMurray JJ.** Diagnosis and management of heart failure. *BMJ* 308: 321-328, 1994.
3. **Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, Fraser AG, Jaarsma T, Pitsis A, Mohacsi P, Bohm M, Anker S, Dargie H, Brutsaert D and Komajda M.** Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 9: 684-694, 2007.
4. **PAINE R and SMITH JR.** The mechanism of heart failure; a resume of physiologic factors in cardiovascular failure. *Am J Med* 6: 84-102, 1949.
5. **BURCH GE and RAY CT.** A consideration of the mechanism of congestive heart failure. *Am Heart J* 41: 918-946, 1951.
6. **Radford MJ, Arnold JM, Bennett SJ, Cinquegrani MP, Cleland JG, Havranek EP, Heidenreich PA, Rutherford JD, Spertus JA, Stevenson LW, Goff DC, Grover FL, Malenka DJ, Peterson ED and Redberg RF.** ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America. *Circulation* 112: 1888-1916, 2005.
7. **Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Tendera M, Auricchio A, Bax J, Bohm M, Corra U, della BP, Elliott PM, Follath F, Gheorghide M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW, Zamorano JL and Zannad F.** ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur J Heart Fail* 10: 933-989, 2008.
8. **Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, Levy D, Kannel WB and Vasan RS.** Long-term trends in the incidence of heart failure after myocardial infarction. *Circulation* 118: 2057-2062, 2008.
9. **Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L and Aukrust P.** Role of inflammation in the progression of heart failure. *Curr Cardiol Rep* 9: 236-241, 2007.

10. **Mann DL.** Inflammatory mediators and the failing heart: past, present, and the foreseeable future. *Circ Res* 91: 988-998, 2002.
11. **Sharma R, Coats AJ and Anker SD.** The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. *Int J Cardiol* 72: 175-186, 2000.
12. **Braunwald E and Pfeffer MA.** Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. *Am J Cardiol* 68: 1D-6D, 1991.
13. **Sutton M, Plappert T, Spiegel A, Raichlen J, Douglas P, Reichek N and Edmunds L.** Early postoperative changes in left ventricular chamber size, architecture, and function in aortic stenosis and aortic regurgitation and their relation to intraoperative changes in afterload: a prospective two-dimensional echocardiographic study. *Circulation* 76: 77-89, 1987.
14. **Lamas GA and Pfeffer MA.** Left ventricular remodeling after acute myocardial infarction: clinical course and beneficial effects of angiotensin-converting enzyme inhibition. *Am Heart J* 121: 1194-1202, 1991.
15. **Bangalore S, Messerli FH, Kostis JB and Pepine CJ.** Cardiovascular protection using beta-blockers: a critical review of the evidence. *J Am Coll Cardiol* 50: 563-572, 2007.
16. **Sallach JA and Goldstein S.** Use of beta-blockers in congestive heart failure. *Ann Med* 35: 259-266, 2003.
17. **Werner C, Baumhakel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S and Bohm M.** RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. *Clin Res Cardiol* 97: 418-431, 2008.
18. **Ezekowitz JA and McAlister FA.** Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. *Eur Heart J* 2008.
19. **Lefkowitz RJ.** G protein-coupled receptors and receptor kinases: from molecular biology to potential therapeutic applications. *Nat Biotechnol* 14: 283-286, 1996.
20. **Rockman HA, Koch WJ and Lefkowitz RJ.** Seven-transmembrane-spanning receptors and heart function. *Nature* 415: 206-212, 2002.
21. **Bockaert J and Pin JP.** Molecular tinkering of G protein-coupled receptors: an evolutionary success. *EMBO J* 18: 1723-1729, 1999.
22. **Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjeksus J, Wikstrand J, El AD, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S and Deedwania P.** Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *JAMA* 283: 1295-1302, 2000.
23. **Motte S, McEntee K and Naeije R.** Endothelin receptor antagonists. *Pharmacol Ther* 110: 386-414, 2006.
24. **Frey N, Katus HA, Olson EN and Hill JA.** Hypertrophy of the heart: a new therapeutic target? *Circulation* 109: 1580-1589, 2004.

25. **Frey N and Olson EN.** Cardiac hypertrophy: the good, the bad, and the ugly. *Annu Rev Physiol* 65: 45-79, 2003.
26. **Levy D, Garrison RJ, Savage DD, Kannel WB and Castelli WP.** Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med* 322: 1561-1566, 1990.
27. **Tomomatsu T, Ueba Y, Kondo Y, Oda M and Ijiri Y.** Catecholamine in congestive heart failure. II. *Jpn Heart J* 8: 242-251, 1967.
28. **Ijiri Y.** Studies on plasma catecholamines in congestive heart failure. *Jpn Circ J* 36: 35-46, 1972.
29. **Dorn GW and Force T.** Protein kinase cascades in the regulation of cardiac hypertrophy. *J Clin Invest* 115: 527-537, 2005.
30. **Dorn GW.** Physiologic growth and pathologic genes in cardiac development and cardiomyopathy. *Trends Cardiovasc Med* 15: 185-189, 2005.
31. **D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB and Dorn GW.** Transgenic Galphaq overexpression induces cardiac contractile failure in mice. *Proc Natl Acad Sci U S A* 94: 8121-8126, 1997.
32. **Sakata Y, Hoit BD, Liggett SB, Walsh RA and Dorn GW.** Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. *Circulation* 97: 1488-1495, 1998.
33. **Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ and Koch WJ.** Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. *Science* 280: 574-577, 1998.
34. **Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, Allen LF and Lefkowitz RJ.** Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. *Proc Natl Acad Sci U S A* 91: 10109-10113, 1994.
35. **Hein L, Stevens ME, Barsh GS, Pratt RE, Kobilka BK and Dzau VJ.** Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. *Proc Natl Acad Sci U S A* 94: 6391-6396, 1997.
36. **Molkentin JD and Dorn GW.** Cytoplasmic signaling pathways that regulate cardiac hypertrophy. *Annu Rev Physiol* 63: 391-426, 2001.
37. **Molkentin JD.** Calcineurin and beyond: cardiac hypertrophic signaling. *Circ Res* 87: 731-738, 2000.
38. **Liggett SB.** Cardiac 7-transmembrane-spanning domain receptor portfolios: diversify, diversify, diversify. *J Clin Invest* 116: 875-877, 2006.
39. **Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K and Masaki T.** A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 332: 411-415, 1988.
40. **Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K and Masaki T.** The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. *Proc Natl Acad Sci U S A* 86: 2863-2867, 1989.

41. **Ishikawa T, Yanagisawa M, Kimura S, Goto K and Masaki T.** Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. *Am J Physiol* 255: H970-H973, 1988.
42. **Ishikawa T, Yanagisawa M, Kimura S, Goto K and Masaki T.** Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide. *Pflugers Arch* 413: 108-110, 1988.
43. **Kramer BK, Smith TW and Kelly RA.** Endothelin and increased contractility in adult rat ventricular myocytes. Role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na(+)-H+ exchanger. *Circ Res* 68: 269-279, 1991.
44. **Kinnunen P, Szokodi I, Nicholls MG and Ruskoaho H.** Impact of NO on ET-1- and AM-induced inotropic responses: potentiation by combined administration. *Am J Physiol Regul Integr Comp Physiol* 279: R569-R575, 2000.
45. **Fujitani Y, Ninomiya H, Okada T, Urade Y and Masaki T.** Suppression of endothelin-1-induced mitogenic responses of human aortic smooth muscle cells by interleukin-1 beta. *J Clin Invest* 95: 2474-2482, 1995.
46. **Giannessi D, Del Ry S and Vitale RL.** The role of endothelins and their receptors in heart failure. *Pharmacol Res* 43: 111-126, 2001.
47. **Kedzierski RM and Yanagisawa M.** Endothelin system: the double-edged sword in health and disease. *Annu Rev Pharmacol Toxicol* 41: 851-876, 2001.
48. **Kirkby NS, Hadoke PW, Bagnall AJ and Webb DJ.** The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? *Br J Pharmacol* 153: 1105-1119, 2008.
49. **Kurihara Y, Kurihara H, Oda H, Maemura K, Nagai R, Ishikawa T and Yazaki Y.** Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. *J Clin Invest* 96: 293-300, 1995.
50. **Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, Clouthier DE and Yanagisawa M.** Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. *J Clin Invest* 105: 1373-1382, 2000.
51. **Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D and Yanagisawa M.** ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. *Cell* 78: 473-485, 1994.
52. **Emoto N and Yanagisawa M.** Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. *J Biol Chem* 270: 15262-15268, 1995.
53. **Valdenaire O, Rohrbacher E and Mattei MG.** Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). *J Biol Chem* 270: 29794-29798, 1995.
54. **Schweizer A, Valdenaire O, Nelbock P, Deuschle U, Dumas Milne Edwards JB, Stumpf JG and Loffler BM.** Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. *Biochem J* 328 (Pt 3): 871-877, 1997.
55. **Valdenaire O, Lepailleur-Enouf D, Egidy G, Thouard A, Barret A, Vranckx R, Tougaard C and Michel JB.** A fourth isoform of endothelin-converting enzyme (ECE-

- 1) is generated from an additional promoter molecular cloning and characterization. *Eur J Biochem* 264: 341-349, 1999.
56. **Telemaque S, Emoto N, deWit D and Yanagisawa M.** In vivo role of endothelin-converting enzyme-1 as examined by adenovirus-mediated overexpression in rats. *J Cardiovasc Pharmacol* 31 Suppl 1: S548-S550, 1998.
 57. **Shima H, Yamanouchi M, Omori K, Sugiura M, Kawashima K and Sato T.** Endothelin-1 production and endothelin converting enzyme expression by guinea pig airway epithelial cells. *Biochem Mol Biol Int* 37: 1001-1010, 1995.
 58. **Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, Nitta M, Taniguchi K and Marumo F.** Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. *Circ Res* 69: 209-215, 1991.
 59. **Araki M, Hasegawa K, Iwai-Kanai E, Fujita M, Sawamura T, Kakita T, Wada H, Morimoto T and Sasayama S.** Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes. *J Am Coll Cardiol* 36: 1411-1418, 2000.
 60. **Serneri GG, Cecioni I, Vanni S, Panicia R, Bandinelli B, Vetere A, Janming X, Bertolozzi I, Boddi M, Lisi GF, Sani G and Modesti PA.** Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart. *Circ Res* 86: 377-385, 2000.
 61. **Fujisaki H, Ito H, Hirata Y, Tanaka M, Hata M, Lin M, Adachi S, Akimoto H, Marumo F and Hiroe M.** Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. *J Clin Invest* 96: 1059-1065, 1995.
 62. **Piacentini L, Gray M, Honbo NY, Chentoufi J, Bergman M and Karliner JS.** Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. *J Mol Cell Cardiol* 32: 565-576, 2000.
 63. **Fareh J, Touyz RM, Schiffrin EL and Thibault G.** Endothelin-1 and angiotensin II receptors in cells from rat hypertrophied heart. Receptor regulation and intracellular Ca²⁺ modulation. *Circ Res* 78: 302-311, 1996.
 64. **Mulder P, Boujedaini H, Richard V, Derumeaux G, Henry JP, Renet S, Wessale J, Opgenorth T and Thuiliez C.** Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. *Circulation* 102: 491-493, 2000.
 65. **De NG, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD and Vane JR.** Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. *Proc Natl Acad Sci U S A* 85: 9797-9800, 1988.
 66. **Jougasaki M, Schirger JA, Simari RD and Burnett JC, Jr.** Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin. *Hypertension* 32: 917-922, 1998.
 67. **Luscher TF and Barton M.** Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. *Circulation* 102: 2434-2440, 2000.

68. **Saito S, Hirata Y, Imai T and Marumo F.** Autocrine regulation of the endothelin-1 gene in rat endothelial cells. *J Cardiovasc Pharmacol* 26 Suppl 3: S84-S87, 1995.
69. **Haynes WG and Webb DJ.** Contribution of endogenous generation of endothelin-1 to basal vascular tone. *Lancet* 344: 852-854, 1994.
70. **Clozel M, Gray GA, Breu V, Loffler BM and Osterwalder R.** The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. *Biochem Biophys Res Commun* 186: 867-873, 1992.
71. **Watanabe H, Miyazaki H, Kondoh M, Masuda Y, Kimura S, Yanagisawa M, Masaki T and Murakami K.** Two distinct types of endothelin receptors are present on chick cardiac membranes. *Biochem Biophys Res Commun* 161: 1252-1259, 1989.
72. **Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W and Binder BR.** Polar secretion of endothelin-1 by cultured endothelial cells. *J Biol Chem* 267: 16066-16068, 1992.
73. **Wagner OF, Nowotny P, Vierhapper H and Waldhausl W.** Plasma concentrations of endothelin in man: arterio-venous differences and release during venous stasis. *Eur J Clin Invest* 20: 502-505, 1990.
74. **Margulies KB, Hildebrand FL, Jr., Lerman A, Perrella MA and Burnett JC, Jr.** Increased endothelin in experimental heart failure. *Circulation* 82: 2226-2230, 1990.
75. **Lerman A, Kubo SH, Tschumperlin LK and Burnett JC, Jr.** Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. *J Am Coll Cardiol* 20: 849-853, 1992.
76. **Rodeheffer RJ, Lerman A, Heublein DM and Burnett JC, Jr.** Increased plasma concentrations of endothelin in congestive heart failure in humans. *Mayo Clin Proc* 67: 719-724, 1992.
77. **McMurray JJ, Ray SG, Abdullah I, Dargie HJ and Morton JJ.** Plasma endothelin in chronic heart failure. *Circulation* 85: 1374-1379, 1992.
78. **Stewart DJ, Cernacek P, Costello KB and Rouleau JL.** Elevated endothelin-1 in heart failure and loss of normal response to postural change. *Circulation* 85: 510-517, 1992.
79. **Zimmerman RS.** A potential role for endothelin in congestive heart failure. *Mayo Clin Proc* 67: 801-803, 1992.
80. **Dupuis J, Rouleau JL and Cernacek P.** Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. *Circulation* 98: 1684-1687, 1998.
81. **Kjekshus H, Smiseth OA, Klinge R, Oie E, Hystad ME and Attramadal H.** Regulation of ET: pulmonary release of ET contributes to increased plasma ET levels and vasoconstriction in CHF. *Am J Physiol Heart Circ Physiol* 278: H1299-H1310, 2000.
82. **Miyauchi T and Masaki T.** Pathophysiology of endothelin in the cardiovascular system. *Annu Rev Physiol* 61: 391-415, 1999.
83. **Yoshizumi M, Kurihara H, Sugiyama T, Takaku F, Yanagisawa M, Masaki T and Yazaki Y.** Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. *Biochem Biophys Res Commun* 161: 859-864, 1989.

84. **Malek A and Izumo S.** Physiological fluid shear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium. *Am J Physiol* 263: C389-C396, 1992.
85. **Abassi ZA, Tate JE, Golomb E and Keiser HR.** Role of neutral endopeptidase in the metabolism of endothelin. *Hypertension* 20: 89-95, 1992.
86. **Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M and Nishikibe M.** Clearance of circulating endothelin-1 by ETB receptors in rats. *Biochem Biophys Res Commun* 199: 1461-1465, 1994.
87. **Dupuis J, Goresky CA and Fournier A.** Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. *J Appl Physiol* 81: 1510-1515, 1996.
88. **Cernacek P and Stewart DJ.** Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. *Biochem Biophys Res Commun* 161: 562-567, 1989.
89. **Hiroe M, Hirata Y, Fujita N, Umezawa S, Ito H, Tsujino M, Koike A, Nogami A, Takamoto T and Marumo F.** Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. *Am J Cardiol* 68: 1114-1115, 1991.
90. **Omland T, Lie RT, Aakvaag A, Aarsland T and Dickstein K.** Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. *Circulation* 89: 1573-1579, 1994.
91. **Love MP, Haynes WG, Gray GA, Webb DJ and McMurray JJ.** Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. *Circulation* 94: 2131-2137, 1996.
92. **Wada A, Tsutamoto T, Fukai D, Ohnishi M, Maeda K, Hisanaga T, Maeda Y, Matsuda Y and Kinoshita M.** Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. *J Am Coll Cardiol* 30: 1385-1392, 1997.
93. **Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R and Bertel O.** Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. *Lancet* 346: 732-736, 1995.
94. **Cody RJ, Haas GJ, Binkley PF, Capers Q and Kelley R.** Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. *Circulation* 85: 504-509, 1992.
95. **Ooi H, Colucci WS and Givertz MM.** Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. *Circulation* 106: 1618-1621, 2002.
96. **Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayashi M, Goto K and Sugishita Y.** Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. *J Am Coll Cardiol* 28: 1580-1588, 1996.
97. **Stewart DJ.** Endothelin in cardiopulmonary disease: factor paracrine vs neurohumoral. *Eur Heart J* 14 Suppl I: 48-54, 1993.

98. **Tsutamoto T, Wada A, Maeda Y, Adachi T and Kinoshita M.** Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. *J Am Coll Cardiol* 23: 1427-1433, 1994.
99. **Johnson W, Omland T, Hall C, Lucas C, Myking OL, Collins C, Pfeffer M, Rouleau JL and Stevenson LW.** Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. *J Am Coll Cardiol* 39: 1623-1629, 2002.
100. **Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K and Sugishita Y.** Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. *Nature* 384: 353-355, 1996.
101. **Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F and Rubin LJ.** Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet* 358: 1119-1123, 2001.
102. **Rubin LJ and Roux S.** Bosentan: a dual endothelin receptor antagonist. *Expert Opin Investig Drugs* 11: 991-1002, 2002.
103. **Torre-Amione G, Durand JB, Nagueh S, Vooletich MT, Kobrin I and Pratt C.** A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. *Chest* 120: 460-466, 2001.
104. **Torre-Amione G, Young JB, Durand J, Bozkurt B, Mann DL, Kobrin I and Pratt CM.** Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. *Circulation* 103: 973-980, 2001.
105. **Coletta AP and Cleland JG.** Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. *Eur J Heart Fail* 3: 747-750, 2001.
106. **Cotter G, Kiowski W, Kaluski E, Kobrin I, Milovanov O, Marmor A, Jafari J, Reisin L, Krakover R, Vered Z and Caspi A.** Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure. *Eur J Heart Fail* 3: 457-461, 2001.
107. **Schalcher C, Cotter G, Reisin L, Bertel O, Kobrin I, Guyene TT and Kiowski W.** The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. *Am Heart J* 142: 340-349, 2001.
108. **O'Connor CM, Gattis WA, Adams KF, Jr., Shah MR, Frey A and Gheorghiade M.** Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). *Am Heart J* 145: S58-S59, 2003.
109. **Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z and Cotter G.** RITZ-5: randomized intravenous Tezosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. *J Am Coll Cardiol* 41: 204-210, 2003.

110. **McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M and Kobrin I.** Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. *JAMA* 298: 2009-2019, 2007.
111. **Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Frey A, Rainisio M and Kobrin I.** Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). *Am Heart J* 150: 46-53, 2005.
112. **Sutsch G, Kiowski W, Yan XW, Hunziker P, Christen S, Strobel W, Kim JH, Rickenbacher P and Bertel O.** Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. *Circulation* 98: 2262-2268, 1998.
113. **Mylona P and Cleland JG.** Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. *Eur J Heart Fail* 1: 197-200, 1999.
114. **Teerlink JR.** Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? *J Card Fail* 8: 124-127, 2002.
115. **Kalra PR, Moon JC and Coats AJ.** Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? *Int J Cardiol* 85: 195-197, 2002.
116. **Luscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, Dietz R, Rousson V, Hurlimann D, Philipp S, Notter T, Noll G and Ruschitzka F.** Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). *Circulation* 106: 2666-2672, 2002.
117. **Battistini B, Berthiaume N, Kelland NF, Webb DJ and Kohan DE.** Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. *Exp Biol Med (Maywood)* 231: 653-695, 2006.
118. **Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F and Luscher TF.** Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. *Lancet* 364: 347-354, 2004.
119. **Levine B, Kalman J, Mayer L, Fillit HM and Packer M.** Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. *N Engl J Med* 323: 236-241, 1990.
120. **Eiken HG, Oie E, Damas JK, Yndestad A, Bjerkeli V, Aass H, Simonsen S, Geiran OR, Tonnessen T, Christensen G, Froland SS, Gullestad L, Attramadal H and Aukrust P.** Myocardial gene expression of leukaemia inhibitory factor, interleukin- 6 and glycoprotein 130 in end-stage human heart failure. *Eur J Clin Invest* 31: 389-397, 2001.

121. **Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G and Bauersachs J.** Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. *Cardiovasc Res* 57: 749-756, 2003.
122. **Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJ and Anker SD.** Plasma cytokine parameters and mortality in patients with chronic heart failure. *Circulation* 102: 3060-3067, 2000.
123. **Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Fujii M, Matsumoto T, Yamamoto T, Wang X, Asai S, Tsuji T, Tanaka H, Saito Y, Kuwahara K, Nakao K and Kinoshita M.** Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. *J Am Coll Cardiol* 38: 1485-1490, 2001.
124. **Hara M, Matsumori A, Ono K, Kido H, Hwang MW, Miyamoto T, Iwasaki A, Okada M, Nakatani K and Sasayama S.** Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro. *Circulation* 100: 1443-1449, 1999.
125. **Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M and Kinoshita M.** Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. *J Am Coll Cardiol* 31: 391-398, 1998.
126. **Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB and Mann DL.** Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). *J Am Coll Cardiol* 27: 1201-1206, 1996.
127. **Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW and LeJemtel TH.** Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. *J Am Coll Cardiol* 28: 964-971, 1996.
128. **Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, Nordoy I, Aass H, Espevik T, Simonsen S, Froland SS and Gullestad L.** Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 83: 376-382, 1999.
129. **Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG and Mann DL.** Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. *Circulation* 104: 826-831, 2001.
130. **Yang LL, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M and Stewart DJ.** Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. *Circulation* 109: 255-261, 2004.
131. **von Haehling S, Jankowska EA and Anker SD.** Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implications. *Basic Res Cardiol* 99: 18-28, 2004.
132. **Gullestad L and Aukrust P.** Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. *Am J Cardiol* 95: 17C-23C, 2005.

133. **Gullestad L, Ueland T, Fjeld JG, Holt E, Gundersen T, Breivik K, Folling M, Hodt A, Skardal R, Kjekshus J, Andreassen A, Kjekshus E, Wergeland R, Yndestad A, Froland SS, Semb AG and Aukrust P.** Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. *Circulation* 112: 3408-3414, 2005.
134. **Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Froland SS and Aukrust P.** Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. *Circulation* 103: 220-225, 2001.
135. **Coletta AP, Clark AL, Banarjee P and Cleland JG.** Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. *Eur J Heart Fail* 4: 559-561, 2002.
136. **Premont RT, Inglese J and Lefkowitz RJ.** Protein kinases that phosphorylate activated G protein-coupled receptors. *FASEB J* 9: 175-182, 1995.
137. **Brodde OE, Broede A, Daul A, Kunde K and Michel MC.** Receptor systems in the non-failing human heart. *Basic Res Cardiol* 87 Suppl 1: 1-14, 1992.
138. **Brodde OE, Hillemann S, Kunde K, Vogelsang M and Zerkowski HR.** Receptor systems affecting force of contraction in the human heart and their alterations in chronic heart failure. *J Heart Lung Transplant* 11: S164-S174, 1992.
139. **Xiao RP, Cheng H, Zhou YY, Kuschel M and Lakatta EG.** Recent advances in cardiac beta(2)-adrenergic signal transduction. *Circ Res* 85: 1092-1100, 1999.
140. **Xiao RP and Lakatta EG.** Beta 1-adrenoceptor stimulation and beta 2-adrenoceptor stimulation differ in their effects on contraction, cytosolic Ca²⁺, and Ca²⁺ current in single rat ventricular cells. *Circ Res* 73: 286-300, 1993.
141. **Brodde OE, Schuler S, Kretsch R, Brinkmann M, Borst HG, Hetzer R, Reidemeister JC, Warnecke H and Zerkowski HR.** Regional distribution of beta-adrenoceptors in the human heart: coexistence of functional beta 1- and beta 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. *J Cardiovasc Pharmacol* 8: 1235-1242, 1986.
142. **Brodde OE, Zerkowski HR, Doetsch N, Motomura S, Khamssi M and Michel MC.** Myocardial beta-adrenoceptor changes in heart failure: concomitant reduction in beta 1- and beta 2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. *J Am Coll Cardiol* 14: 323-331, 1989.
143. **Khamssi M and Brodde OE.** The role of cardiac beta1- and beta2-adrenoceptor stimulation in heart failure. *J Cardiovasc Pharmacol* 16 Suppl 5: S133-S137, 1990.
144. **Hausdorff WP, Hnатовich M, O'Dowd BF, Caron MG and Lefkowitz RJ.** A mutation of the beta 2-adrenergic receptor impairs agonist activation of adenylyl cyclase without affecting high affinity agonist binding. Distinct molecular determinants of the receptor are involved in physical coupling to and functional activation of Gs. *J Biol Chem* 265: 1388-1393, 1990.
145. **Brodde OE.** Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. *Pharmacol Rev* 43: 203-242, 1991.
146. **Hausdorff WP, Caron MG and Lefkowitz RJ.** Turning off the signal: desensitization of beta-adrenergic receptor function. *FASEB J* 4: 2881-2889, 1990.

147. **Stadel JM, Nambi P, Shorr RG, Sawyer DF, Caron MG and Lefkowitz RJ.** Catecholamine-induced desensitization of turkey erythrocyte adenylate cyclase is associated with phosphorylation of the beta-adrenergic receptor. *Proc Natl Acad Sci U S A* 80: 3173-3177, 1983.
148. **Krupnick JG and Benovic JL.** The role of receptor kinases and arrestins in G protein-coupled receptor regulation. *Annu Rev Pharmacol Toxicol* 38: 289-319, 1998.
149. **Penela P, Ribas C and Mayor F, Jr.** Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. *Cell Signal* 15: 973-981, 2003.
150. **Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA and Lefkowitz RJ.** Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. *Science* 268: 1350-1353, 1995.
151. **Drazner MH, Poppel KC, Dyer S, Grant AO, Koch WJ and Lefkowitz RJ.** Potentiation of beta-adrenergic signaling by adenoviral-mediated gene transfer in adult rabbit ventricular myocytes. *J Clin Invest* 99: 288-296, 1997.
152. **Ungerer M, Bohm M, Elce JS, Erdmann E and Lohse MJ.** Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. *Circulation* 87: 454-463, 1993.
153. **Ungerer M, Parruti G, Bohm M, Puzicha M, DeBlasi A, Erdmann E and Lohse MJ.** Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. *Circ Res* 74: 206-213, 1994.
154. **Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J, Jr., Lefkowitz RJ and Koch WJ.** Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. *Proc Natl Acad Sci U S A* 95: 7000-7005, 1998.
155. **White DC, Hata JA, Shah AS, Glower DD, Lefkowitz RJ and Koch WJ.** Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. *Proc Natl Acad Sci U S A* 97: 5428-5433, 2000.
156. **Harding VB, Jones LR, Lefkowitz RJ, Koch WJ and Rockman HA.** Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. *Proc Natl Acad Sci U S A* 98: 5809-5814, 2001.
157. **Shah AS, White DC, Emani S, Kypson AP, Lilly RE, Wilson K, Glower DD, Lefkowitz RJ and Koch WJ.** In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. *Circulation* 103: 1311-1316, 2001.
158. **Williams ML, Hata JA, Schroder J, Rampersaud E, Petrofski J, Jakoi A, Milano CA and Koch WJ.** Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts. *Circulation* 109: 1590-1593, 2004.
159. **Raake PW, Vinge LE, Gao E, Boucher M, Rengo G, Chen X, DeGeorge BR, Jr., Matkovich S, Houser SR, Most P, Eckhart AD, Dorn GW and Koch WJ.** G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. *Circ Res* 103: 413-422, 2008.
160. **Iaccarino G, Rockman HA, Shotwell KF, Tomhave ED and Koch WJ.** Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. *Am J Physiol* 275: H1298-H1306, 1998.

161. **Eckhart AD, Duncan SJ, Penn RB, Benovic JL, Lefkowitz RJ and Koch WJ.** Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. *Circ Res* 86: 43-50, 2000.
162. **Vinge LE, Andressen KW, Attramadal T, Andersen GO, Ahmed MS, Peppel K, Koch WJ, Freedman NJ, Levy FO, Skomedal T, Osnes JB and Attramadal H.** Substrate specificities of g protein-coupled receptor kinase-2 and -3 at cardiac myocyte receptors provide basis for distinct roles in regulation of myocardial function. *Mol Pharmacol* 72: 582-591, 2007.
163. **Ferguson SS, Menard L, Barak LS, Koch WJ, Colapietro AM and Caron MG.** Role of phosphorylation in agonist-promoted beta 2-adrenergic receptor sequestration. Rescue of a sequestration-defective mutant receptor by beta ARK1. *J Biol Chem* 270: 24782-24789, 1995.
164. **Oppermann M, Diverse-Pierluissi M, Drazner MH, Dyer SL, Freedman NJ, Peppel KC and Lefkowitz RJ.** Monoclonal antibodies reveal receptor specificity among G-protein-coupled receptor kinases. *Proc Natl Acad Sci U S A* 93: 7649-7654, 1996.
165. **Ishii K, Chen J, Ishii M, Koch WJ, Freedman NJ, Lefkowitz RJ and Coughlin SR.** Inhibition of thrombin receptor signaling by a G-protein coupled receptor kinase. Functional specificity among G-protein coupled receptor kinases. *J Biol Chem* 269: 1125-1130, 1994.
166. **Daaka Y, Pitcher JA, Richardson M, Stoffel RH, Robishaw JD and Lefkowitz RJ.** Receptor and G betagamma isoform-specific interactions with G protein-coupled receptor kinases. *Proc Natl Acad Sci U S A* 94: 2180-2185, 1997.
167. **Walker JK, Peppel K, Lefkowitz RJ, Caron MG and Fisher JT.** Altered airway and cardiac responses in mice lacking G protein-coupled receptor kinase 3. *Am J Physiol* 276: R1214-R1221, 1999.
168. **Dupuis J, Stewart DJ, Cernacek P and Gosselin G.** Human pulmonary circulation is an important site for both clearance and production of endothelin-1. *Circulation* 94: 1578-1584, 1996.
169. **Kobayashi T, Miyauchi T, Sakai S, Maeda S, Yamaguchi I, Goto K and Sugishita Y.** Down-regulation of ET(B) receptor, but not ET(A) receptor, in congestive lung secondary to heart failure. Are marked increases in circulating endothelin-1 partly attributable to decreases in lung ET(B) receptor-mediated clearance of endothelin-1? *Life Sci* 62: 185-193, 1998.
170. **Dupuis J, Goresky CA and Stewart DJ.** Pulmonary removal and production of endothelin in the anesthetized dog. *J Appl Physiol* 76: 694-700, 1994.
171. **Spinale FG, Eble DM, Mukherjee R, Johnson WS and Walker JD.** Left ventricular and myocyte structure and function following chronic ventricular tachycardia in rabbits. *Basic Res Cardiol* 89: 456-467, 1994.
172. **Yarbrough WM and Spinale FG.** Large animal models of congestive heart failure: a critical step in translating basic observations into clinical applications. *J Nucl Cardiol* 10: 77-86, 2003.
173. **Armstrong PW, Stopps TP, Ford SE and De Bold AJ.** Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. *Circulation* 74: 1075-1084, 1986.

174. **Hendrick DA, Smith AC, Kratz JM, Crawford FA and Spinale FG.** The pig as a model of tachycardia and dilated cardiomyopathy. *Lab Anim Sci* 40: 495-501, 1990.
175. **Spinale FG, Hendrick DA, Crawford FA, Smith AC, Hamada Y and Carabello BA.** Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. *Am J Physiol* 259: H218-H229, 1990.
176. **Spinale FG, Holzgreffe HH, Mukherjee R, Hird RB, Walker JD, Arnim-Barker A, Powell JR and Koster WH.** Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function. *Circulation* 92: 562-578, 1995.
177. **Kribbs SB, Clair MJ, Krombach RS, Hendrick JW, Thomas PB, Keever AT, Houch WV, Mukherjee R and Spinale FG.** Pulmonary hemodynamics and endothelin levels in pacing-induced heart failure: during rest and exercise. *J Card Fail* 3: 263-270, 1997.
178. **Doggrell SA and Brown L.** Present and future pharmacotherapy for heart failure. *Expert Opin Pharmacother* 3: 915-930, 2002.
179. **Wada A, Tsutamoto T, Ohnishi M, Sawaki M, Fukai D, Maeda Y and Kinoshita M.** Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. *Circulation* 99: 570-577, 1999.
180. **Wada A, Ohnishi M, Tsutamoto T, Fujii M, Matsumoto T, Yamamoto T, Wang X and Kinoshita M.** Chronic effects of an endothelin-converting enzyme inhibitor on cardiorenal and hormonal function in heart failure. *Clin Sci (Lond)* 103 Suppl 1: 254S-257S, 2002.
181. **Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY and Yokoyama M.** Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. *Hypertension* 45: 1145-1152, 2005.
182. **Mulder P, Barbier S, Monteil C, Jeng AY, Henry JP, Renet S and Thuillez C.** Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure. *J Cardiovasc Pharmacol* 43: 489-494, 2004.
183. **Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R and Koopman PA.** Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. *Am J Cardiol* 94: 237-239, 2004.
184. **Cerdeira AS, Bras-Silva C and Leite-Moreira AF.** Endothelin-converting enzyme inhibitors: their application in cardiovascular diseases. *Rev Port Cardiol* 27: 385-408, 2008.
185. **Hoang MV and Turner AJ.** Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. *Biochem J* 327 (Pt 1): 23-26, 1997.
186. **Corti R, Burnett JC, Jr., Rouleau JL, Ruschitzka F and Luscher TF.** Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? *Circulation* 104: 1856-1862, 2001.
187. **Jankov RP, Luo X, Belcastro R, Copland I, Frndova H, Lye SJ, Hoidal JR, Post M and Tanswell AK.** Gadolinium chloride inhibits pulmonary macrophage influx and

- prevents O(2)-induced pulmonary hypertension in the neonatal rat. *Pediatr Res* 50: 172-183, 2001.
188. **Hardonk MJ, Dijkhuis FW, Hulstaert CE and Koudstaal J.** Heterogeneity of rat liver and spleen macrophages in gadolinium chloride-induced elimination and repopulation. *J Leukoc Biol* 52: 296-302, 1992.
 189. **Spencer AJ, Wilson SA, Batchelor J, Reid A, Rees J and Harpur E.** Gadolinium chloride toxicity in the rat. *Toxicol Pathol* 25: 245-255, 1997.
 190. **Brown AP, Harkema JR, Schultze AE, Roth RA and Ganey PE.** Gadolinium chloride pretreatment protects against hepatic injury but predisposes the lungs to alveolitis after lipopolysaccharide administration. *Shock* 7: 186-192, 1997.
 191. **Bukara M and Bautista AP.** Acute alcohol intoxication and gadolinium chloride attenuate endotoxin-induced release of CC chemokines in the rat. *Alcohol* 20: 193-203, 2000.
 192. **Giakoustidis DE, Iliadis S, Tsantilas D, Papageorgiou G, Kontos N, Kostopoulou E, Botsoglou NA, Gerasimidis T and Dimitriadou A.** Blockade of Kupffer cells by gadolinium chloride reduces lipid peroxidation and protects liver from ischemia/reperfusion injury. *Hepatogastroenterology* 50: 1587-1592, 2003.
 193. **Iimuro Y, Yamamoto M, Kohno H, Itakura J, Fujii H and Matsumoto Y.** Blockade of liver macrophages by gadolinium chloride reduces lethality in endotoxemic rats--analysis of mechanisms of lethality in endotoxemia. *J Leukoc Biol* 55: 723-728, 1994.
 194. **Keller SA, Paxian M, Ashburn JH, Clemens MG and Huynh T.** Kupffer cell ablation improves hepatic microcirculation after trauma and sepsis. *J Trauma* 58: 740-749, 2005.
 195. **Lazar G, Jr., Lazar G, Kaszaki J, Olah J, Kiss I and Husztik E.** Inhibition of anaphylactic shock by gadolinium chloride-induced Kupffer cell blockade. *Agents Actions* 41 Spec No: C97-C98, 1994.
 196. **Nicolosi AC, Kwok CS and Bosnjak ZJ.** Antagonists of stretch-activated ion channels restore contractile function in hamster dilated cardiomyopathy. *J Heart Lung Transplant* 23: 1003-1007, 2004.
 197. **Vinge LE, Oie E, Andersson Y, Groggaard HK, Andersen G and Attramadal H.** Myocardial distribution and regulation of GRK and beta-arrestin isoforms in congestive heart failure in rats. *Am J Physiol Heart Circ Physiol* 281: H2490-H2499, 2001.
 198. **Lin F, Owens WA, Chen S, Stevens ME, Kesteven S, Arthur JF, Woodcock EA, Feneley MP and Graham RM.** Targeted alpha(1A)-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy. *Circ Res* 89: 343-350, 2001.
 199. **Grupp IL, Lorenz JN, Walsh RA, Boivin GP and Rindt H.** Overexpression of alpha1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy. *Am J Physiol* 275: H1338-H1350, 1998.
 200. **Lemire I, Ducharme A, Tardif JC, Poulin F, Jones LR, Allen BG, Hebert TE and Rindt H.** Cardiac-directed overexpression of wild-type alpha1B-adrenergic receptor induces dilated cardiomyopathy. *Am J Physiol Heart Circ Physiol* 281: H931-H938, 2001.

201. **Manning BS, Shotwell K, Mao L, Rockman HA and Koch WJ.** Physiological induction of a beta-adrenergic receptor kinase inhibitor transgene preserves ss-adrenergic responsiveness in pressure-overload cardiac hypertrophy. *Circulation* 102: 2751-2757, 2000.
202. **Tachibana H, Naga Prasad SV, Lefkowitz RJ, Koch WJ and Rockman HA.** Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. *Circulation* 111: 591-597, 2005.
203. **Li Z, Laugwitz KL, Pinkernell K, Pragst I, Baumgartner C, Hoffmann E, Rosport K, Munch G, Moretti A, Humrich J, Lohse MJ and Ungerer M.** Effects of two Gbetagamma-binding proteins--N-terminally truncated phosphoinositide 3-kinase and beta-adrenergic receptor kinase C terminus (betaARKct)--in heart failure. *Gene Ther* 10: 1354-1361, 2003.
204. **Naga Prasad SV, Esposito G, Mao L, Koch WJ and Rockman HA.** Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. *J Biol Chem* 275: 4693-4698, 2000.
205. **Naga Prasad SV, Barak LS, Rapacciuolo A, Caron MG and Rockman HA.** Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration. *J Biol Chem* 276: 18953-18959, 2001.
206. **Nienaber JJ, Tachibana H, Naga Prasad SV, Esposito G, Wu D, Mao L and Rockman HA.** Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. *J Clin Invest* 112: 1067-1079, 2003.
207. **Perrino C, Naga Prasad SV, Patel M, Wolf MJ and Rockman HA.** Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. *J Am Coll Cardiol* 45: 1862-1870, 2005.
208. **Winstel R, Ihlenfeldt HG, Jung G, Krasel C and Lohse MJ.** Peptide inhibitors of G protein-coupled receptor kinases. *Biochem Pharmacol* 70: 1001-1008, 2005.